tegafur has been researched along with Cancer of Gastrointestinal Tract in 57 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "For prevention of the chemotherapy-induced stomatitis we administered allopurinol mouthwash to 15 out of 38 patients who underwent PMUE regimen." | 7.68 | [Prophylactic effect of allopurinol mouthwash against stomatitis induced by the chemotherapy (PMUE regimen) for gastrointestinal malignancies]. ( Anada, E; Fujimura, T; Fujita, H; Haryo, S; Sawasaki, K; Shima, Y; Shiota, S, 1991) |
| "In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups)." | 5.04 | [A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)]. ( Arnold, H; Drings, P; Geldmacher, J; Hartwich, G; Kredel, L; Mayer, M; Neidhardt, B; Queisser, W; Rösch, W; Schaefer, J; von Oldershausen, HF; Wahrendorf, J, 1979) |
| "For prevention of the chemotherapy-induced stomatitis we administered allopurinol mouthwash to 15 out of 38 patients who underwent PMUE regimen." | 3.68 | [Prophylactic effect of allopurinol mouthwash against stomatitis induced by the chemotherapy (PMUE regimen) for gastrointestinal malignancies]. ( Anada, E; Fujimura, T; Fujita, H; Haryo, S; Sawasaki, K; Shima, Y; Shiota, S, 1991) |
| "Nutritional therapy is used to reduce the adverse events (AEs) of anticancer drugs." | 2.82 | Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients. ( Hashimoto, T; Honda, H; Kakita, T; Kayahara, T; Kurihara, S; Oikawa, M; Oishi, H; Oyama, A; Shibakusa, T; Tochikubo, K; Tsuchiya, T, 2016) |
| "In a 14-day dosing schedule, the MTD of S-1 was 30 mg/m2 and preliminary evidence of antitumor activity was seen in a North American population with refractory upper gastrointestinal malignancies." | 2.73 | Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer. ( Anbe, H; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Houghton, M; Kulke, MH; Meyerhardt, JA; Regan, E; Ryan, DP; Urrea, P; Zhang, J; Zhu, AX, 2007) |
| " In total, 79 courses were administered with a median of 3 (range 1-6)." | 2.72 | UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors. ( Abad, A; Aranda, E; Carrato, A; Díaz-Rubio, E; Gallego, J; Gómez, A; López, E; Manzano, JL; Sastre, J, 2006) |
| " UFT and other oral 5FU dosing strategies make promising components of combination chemotherapy, deserving further, randomised evaluation." | 2.69 | Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer. ( Cresswell, H; Dent, JT; Papamichael, D; Seymour, MT; Slevin, ML; Wilson, G, 1999) |
| "Fifty of 80 cases had advanced gastric cancer, 30 had pancreatic cancer or other cancers, such as colon cancer, and biliary tract cancer." | 2.66 | [Controlled study of MQF-OK therapy with FT and with UFT on various advanced gastrointestinal cancers. Hirosaki Cooperative Study Group of Cancer Chemotherapy]. ( Baba, T; Furukohori, N; Itoh, T; Kawata, K; Kimura, T; Munakata, A; Saitoh, S; Sakata, Y; Suzuki, H; Tamura, Y, 1988) |
| " Part II of the trial revealed that neither a higher dosage of ftorafur (2 g/m2/day X 5 days) nor the addition of vincristine to both regimens changed the previously obtained results significantly." | 2.65 | Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma. ( Arnold, H; Drings, P; Fritze, D; Geldmacher, J; Hartwich, G; Herrmann, R; Kempf, P; König, H; Meiser, RJ; Nedden, R; Pappas, A; Queisser, W; Schaefer, J; Schnitzler, G; Sievers, H; von Oldershausen, HF; Wahrendorf, J; Westerhausen, M; Witte, S, 1981) |
| "Therapy for patients with advanced gastric cancer is not satisfactory." | 2.43 | Rapid development of S-1 in the west for therapy of advanced gastric carcinoma. ( Ajani, JA, 2006) |
| "Fluorouracil has been used for a long time, remission rates reported range from 0% to 80%." | 2.36 | [Chemotherapy of gastrointestinal tumors (review of the literature)]. ( Mayr, AC, 1978) |
| " The prothrombin time international normalized ratio divided by current warfarin dosage (PT-INR/dose) was measured over time to evaluate warfarin titer in each patient." | 1.43 | Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer. ( Doki, Y; Haraguchi, N; Hata, T; Kudo, T; Mizushima, T; Mori, M; Nishimura, J; Sakai, D; Satoh, T; Takahashi, H; Yamamoto, H, 2016) |
| " Potential predictive pharmacokinetic parameters and pharmacodynamic biomarkers have been found." | 1.38 | Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. ( Allegrini, G; Arrighi, G; Barletta, MT; Bocci, G; Brandi, G; Canu, B; Chericoni, S; Ciarlo, A; Danesi, R; Di Desidero, T; Di Paolo, A; Falcone, A; Fioravanti, A; Fontana, A; Giusiani, M; Kerbel, RS; Loupakis, F; Lucchesi, S; Masi, G; Orlandi, P, 2012) |
| "To report canalicular stenosis as a side effect of the new antineoplastic agent S-1." | 1.33 | Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. ( Ajani, J; Esmaeli, B; Golio, D; Lubecki, L, 2005) |
| "Thirty four patients with advanced gastric cancer (GC), colon cancer (CC) biliary tract cancer (BC) and pancreatic cancer (PC) were treated with a combined chemotherapy of UFT with ADM (UFT-A), or UFT with ADM and CDDP (UFT-AC)." | 1.28 | [Combination chemotherapy of UFT with adriamycin (ADM) and cisplatin (CDDP) for advanced gastrointestinal cancer]. ( Koda, K; Kure, T; Matsunaga, T; Miyazaki, E; Morii, K; Morita, K; Nakajima, K; Nakazawa, O; Terada, S; Tsuji, Y, 1990) |
| "One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks." | 1.27 | [Clinical trial on the effect of tegafur (SF-SP)]. ( Akazawa, S; Futatsuki, K; Hattori, M; Ishibashi, I; Kanda, Y; Sendai, H; Shimada, S, 1984) |
| " Total Ftorafur (FT) results using the same criteria from the UFT phase II study revealed, from a comparison of dosage and disease type, that UFT did not enhance FT side effects; rather, it markedly increases effectiveness." | 1.27 | [Report on nationwide pooled data and cohort investigation in UFT phase II study]. ( Kimura, K; Ota, K; Taguchi, T, 1987) |
| "Ten patients with carcinomatous peritonitis of gastrointestinal cancer have been treated with administrations of CDDP-Ip (50-150 mg/body), in combination with systemic chemotherapy simultaneously combined with sodium thiosulfate (STS) iv in 4 patients." | 1.27 | [Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics]. ( Fukushi, A; Hirayama, M; Koda, K; Kure, T; Morita, K; Nakazawa, O; Takahashi, H; Terada, S; Terui, T; Yoshizaki, N, 1988) |
| " The pharmacologic properties of FT appear to dictate its most useful schedule (continuous oral dosing in multiple doses) and explain why FT alone is not ideal as a 5-FU pro-drug." | 1.27 | Relevance of the pharmacology of oral tegafur to its use as a 5-FU pro-drug. ( Byfield, JE; Frankel, SS; Griffiths, JC; Hornbeck, CL; Sharp, TR, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (38.60) | 18.7374 |
| 1990's | 15 (26.32) | 18.2507 |
| 2000's | 13 (22.81) | 29.6817 |
| 2010's | 6 (10.53) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Luo, D | 1 |
| Wang, L | 1 |
| Chen, X | 1 |
| Xiong, Y | 1 |
| Yi, F | 1 |
| Ding, J | 1 |
| Ding, H | 1 |
| Wei, Y | 1 |
| Zhang, W | 1 |
| Zhang, X | 2 |
| Cao, C | 2 |
| Zhang, Q | 1 |
| Chen, Y | 1 |
| Gu, D | 2 |
| Shen, Y | 1 |
| Gong, Y | 1 |
| Chen, J | 2 |
| Tang, C | 2 |
| Kuang, M | 1 |
| He, M | 1 |
| Tsuchiya, T | 1 |
| Honda, H | 1 |
| Oikawa, M | 1 |
| Kakita, T | 1 |
| Oyama, A | 1 |
| Oishi, H | 1 |
| Tochikubo, K | 1 |
| Hashimoto, T | 1 |
| Kurihara, S | 1 |
| Shibakusa, T | 1 |
| Kayahara, T | 1 |
| Hata, T | 2 |
| Kudo, T | 1 |
| Sakai, D | 1 |
| Takahashi, H | 3 |
| Haraguchi, N | 1 |
| Nishimura, J | 1 |
| Mizushima, T | 1 |
| Yamamoto, H | 1 |
| Doki, Y | 1 |
| Mori, M | 1 |
| Satoh, T | 2 |
| Allegrini, G | 1 |
| Di Desidero, T | 1 |
| Barletta, MT | 1 |
| Fioravanti, A | 1 |
| Orlandi, P | 1 |
| Canu, B | 1 |
| Chericoni, S | 1 |
| Loupakis, F | 1 |
| Di Paolo, A | 1 |
| Masi, G | 1 |
| Fontana, A | 1 |
| Lucchesi, S | 1 |
| Arrighi, G | 1 |
| Giusiani, M | 1 |
| Ciarlo, A | 1 |
| Brandi, G | 1 |
| Danesi, R | 1 |
| Kerbel, RS | 1 |
| Falcone, A | 1 |
| Bocci, G | 1 |
| Sakata, Y | 3 |
| Hoff, PM | 2 |
| Saad, ED | 2 |
| Ajani, JA | 2 |
| Lassere, Y | 1 |
| Wenske, C | 1 |
| Medgyesy, D | 1 |
| Dwivedy, S | 1 |
| Russo, M | 1 |
| Pazdur, R | 1 |
| Yamada, Y | 1 |
| Hamaguchi, T | 1 |
| Goto, M | 1 |
| Muro, K | 1 |
| Matsumura, Y | 1 |
| Shimada, Y | 2 |
| Shirao, K | 1 |
| Nagayama, S | 1 |
| Byström, P | 1 |
| Frödin, JE | 1 |
| Berglund, A | 1 |
| Wilking, N | 1 |
| Glimelius, B | 1 |
| Schöffski, P | 1 |
| Taïeb, J | 1 |
| Desramé, J | 1 |
| Artru, P | 1 |
| Formentini, A | 1 |
| Henne-Bruns, D | 1 |
| Kornmann, M | 1 |
| Esmaeli, B | 1 |
| Golio, D | 1 |
| Lubecki, L | 1 |
| Ajani, J | 1 |
| Sastre, J | 1 |
| Aranda, E | 1 |
| Abad, A | 1 |
| Gallego, J | 1 |
| Manzano, JL | 1 |
| Gómez, A | 1 |
| Carrato, A | 1 |
| López, E | 1 |
| Díaz-Rubio, E | 1 |
| Zhu, AX | 1 |
| Clark, JW | 1 |
| Ryan, DP | 1 |
| Meyerhardt, JA | 1 |
| Enzinger, PC | 1 |
| Earle, CC | 1 |
| Fuchs, CS | 1 |
| Regan, E | 1 |
| Anbe, H | 1 |
| Houghton, M | 1 |
| Zhang, J | 1 |
| Urrea, P | 1 |
| Kulke, MH | 1 |
| Borchard, F | 1 |
| Futatsuki, K | 1 |
| Shimada, S | 1 |
| Kanda, Y | 1 |
| Ishibashi, I | 1 |
| Sendai, H | 1 |
| Akazawa, S | 1 |
| Hattori, M | 1 |
| Kameda, C | 1 |
| Tanaka, T | 1 |
| Shiomi, M | 1 |
| Saka, M | 1 |
| Katsu, K | 1 |
| Itoh, S | 1 |
| Hornbeck, CL | 3 |
| Floyd, RA | 2 |
| Griffiths, JC | 3 |
| Byfield, JE | 3 |
| Klein, HO | 1 |
| Wickramanayake, PD | 1 |
| Voigtmann, R | 1 |
| Löffler, T | 1 |
| Mohr, R | 1 |
| Oerkermann, H | 1 |
| Queisser, W | 2 |
| Schnitzler, G | 1 |
| Schaefer, J | 2 |
| Arnold, H | 2 |
| Drings, P | 2 |
| Fritze, D | 1 |
| Geldmacher, J | 2 |
| Hartwich, G | 3 |
| Herrmann, R | 1 |
| Kempf, P | 1 |
| König, H | 1 |
| Meiser, RJ | 1 |
| Nedden, R | 1 |
| von Oldershausen, HF | 2 |
| Pappas, A | 1 |
| Sievers, H | 1 |
| Wahrendorf, J | 2 |
| Westerhausen, M | 1 |
| Witte, S | 1 |
| Nakazawa, I | 1 |
| Goto, Y | 1 |
| Ouchi, E | 1 |
| Nomura, N | 1 |
| Suzuki, N | 1 |
| Kikuchi, T | 1 |
| Seo, Y | 1 |
| Matsuoka, H | 1 |
| Kakeji, Y | 1 |
| Morita, M | 1 |
| Ohno, S | 1 |
| Matsukuma, A | 1 |
| Tomoda, H | 1 |
| Furusawa, M | 1 |
| Nakamura, M | 1 |
| Katano, M | 1 |
| Yunotani, S | 1 |
| Hisatsugu, T | 1 |
| Sasadomi, E | 1 |
| Masumoto, H | 1 |
| Tsuji, Y | 2 |
| Yoshihito, H | 1 |
| Nakamura, T | 1 |
| Watanabe, Y | 1 |
| Nakayama, N | 1 |
| Ohi, M | 1 |
| Kawanishi, J | 1 |
| Handa, H | 1 |
| Honjo, K | 1 |
| Uehara, S | 1 |
| Akiyama, C | 1 |
| Osada, A | 1 |
| Sou, K | 1 |
| Yasaka, N | 1 |
| Ohtake, N | 1 |
| Furue, M | 1 |
| Tamaki, K | 1 |
| Horikoshi, N | 2 |
| Aiba, K | 2 |
| Kanamaru, R | 1 |
| Hasegawa, K | 1 |
| Takeda, S | 2 |
| Taguchi, T | 5 |
| Niitani, H | 1 |
| Furue, H | 1 |
| Kurihara, M | 2 |
| Ogawa, M | 1 |
| Abe, T | 2 |
| Oki, E | 1 |
| Sakaguchi, Y | 1 |
| Toh, Y | 1 |
| Oda, S | 1 |
| Maehara, Y | 3 |
| Yamamoto, N | 1 |
| Sugimachi, K | 3 |
| Shirasaka, T | 1 |
| Araki, H | 1 |
| Suzuki, M | 1 |
| Terashima, M | 1 |
| Mikami, Y | 1 |
| Mitachi, Y | 1 |
| Blanke, CD | 1 |
| Teng, M | 1 |
| Choy, H | 1 |
| Seymour, MT | 1 |
| Dent, JT | 1 |
| Papamichael, D | 1 |
| Wilson, G | 1 |
| Cresswell, H | 1 |
| Slevin, ML | 1 |
| Conroy, T | 1 |
| Paillot, B | 1 |
| Adenis, A | 1 |
| Basaki, Y | 1 |
| Miyadera, K | 1 |
| Yonekura, K | 1 |
| Aoyagi, K | 1 |
| Chikahisa, L | 1 |
| Okabe, S | 1 |
| Hashimoto, A | 1 |
| Kitazato, K | 1 |
| Mayr, AC | 1 |
| Watanabe, A | 1 |
| Hobara, N | 1 |
| Nagashima, H | 1 |
| Blokhina, NG | 1 |
| Smolianskaia, AZ | 1 |
| Aledseev, VM | 1 |
| Sokolova, VD | 1 |
| Maruyama, T | 1 |
| Izumi, T | 1 |
| Miyasaka, K | 1 |
| Yamaya, F | 1 |
| Shirakabe, H | 1 |
| Kamano, T | 1 |
| Kishino, H | 1 |
| Minakami, T | 1 |
| Kredel, L | 1 |
| Mayer, M | 1 |
| Neidhardt, B | 1 |
| Rösch, W | 1 |
| Fujimura, T | 1 |
| Shima, Y | 1 |
| Sawasaki, K | 1 |
| Haryo, S | 1 |
| Fujita, H | 1 |
| Anada, E | 1 |
| Shiota, S | 1 |
| Koda, K | 2 |
| Nakazawa, O | 2 |
| Morita, K | 2 |
| Kure, T | 2 |
| Terada, S | 2 |
| Matsunaga, T | 1 |
| Miyazaki, E | 1 |
| Nakajima, K | 1 |
| Morii, K | 1 |
| Kikuchi, K | 1 |
| Wakui, A | 1 |
| Piccinini, L | 1 |
| Corradini, R | 1 |
| Vandelli, C | 1 |
| Luppi, G | 1 |
| Di Marco, G | 1 |
| Seki, H | 1 |
| Kimura, K | 2 |
| Ota, K | 1 |
| Hirayama, M | 1 |
| Fukushi, A | 1 |
| Terui, T | 1 |
| Yoshizaki, N | 1 |
| Misawa, S | 1 |
| Yashige, H | 1 |
| Nishigaki, H | 1 |
| Horiike, S | 1 |
| Tsuda, S | 1 |
| Takino, T | 1 |
| Taniwaki, M | 1 |
| Tsuji, T | 1 |
| Anai, H | 1 |
| Kusumoto, H | 1 |
| Kusumoto, T | 1 |
| Munakata, A | 1 |
| Baba, T | 1 |
| Saitoh, S | 1 |
| Itoh, T | 1 |
| Tamura, Y | 1 |
| Furukohori, N | 1 |
| Suzuki, H | 1 |
| Kimura, T | 1 |
| Kawata, K | 1 |
| Sharp, TR | 2 |
| Frankel, SS | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062] | Phase 1 | 120 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for tegafur and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Comparison of Platinum/S-1 and Platinum/5-Fluorouracil as First-Line Chemotherapy for Advanced Gastric or Gastroesophageal Junction Cancer: A Meta-Analysis Based on Randomized Controlled Trials.
Topics: Antineoplastic Agents; Coordination Complexes; Disease-Free Survival; Drug Combinations; Drug Therap | 2020 |
Comparison of the efficacy and safety of S-1-based and capecitabine-based regimens in gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluo | 2014 |
Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.
Topics: Antineoplastic Agents; Asian People; Drug Combinations; Fluorouracil; Gastrointestinal Neoplasms; Hu | 2014 |
S-1 for the treatment of gastrointestinal cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothec | 2012 |
UFT and oral leucovorin as radiation sensitizers in rectal and other gastrointestinal malignancies.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Gas | 2003 |
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 2004 |
[Oral 5-FU and digestive cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasm | 2004 |
Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality | 2004 |
Rapid development of S-1 in the west for therapy of advanced gastric carcinoma.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2006 |
[The diffuse endocrine system and the carcinoids of the alimentary tract. Part I: Orthological aspects and common morphological features of the carcinoids (author's transl)].
Topics: Adrenocorticotropic Hormone; Aged; Appendiceal Neoplasms; APUD Cells; Carcinoid Tumor; Carmustine; C | 1982 |
[Gastrointestinal cancer and oral anticancer agents].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Drug Com | 1999 |
[Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Cyc | 1999 |
The role of UFT in combined-modality therapy.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as To | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorourac | 1999 |
[Chemotherapy of gastrointestinal tumors (review of the literature)].
Topics: Ancitabine; Carcinoma, Hepatocellular; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Fl | 1978 |
14 trials available for tegafur and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cystine; | 2016 |
Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Dose-Response Relationship, Drug; Dr | 2003 |
Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up | 2004 |
UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2006 |
Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Comb | 2007 |
Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma.
Topics: Adult; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Huma | 1981 |
[Low-dose FP (5-FU+low-dose CDDP) therapy for far advanced upper gastro-intestinal carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 1995 |
[Outpatient chemotherapy with continuous infusion of 5-fluorouracil (CI 5-FU) and intravenous bolus leucovorin (IVB LV) in advanced gastrointestinal cancer: the second report].
Topics: Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Chemoth | 1995 |
[Phase I study of orally administered UFT plus l-leucovorin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 1998 |
An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Fluorouracil; Gastrointestinal Neop | 1999 |
Epirubicin, cisplatin and oral UFT with leucovorin ('ECU'): a phase I-II study in patients with advanced upper gastrointestinal tract cancer.
Topics: Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy | 1999 |
[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)].
Topics: Adenocarcinoma; Carmustine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestinal Neoplasms; | 1979 |
[Cooperative research of UFT E phase II study. Cooperative Study Group of UFT E in Tohoku Area].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; | 1990 |
[Controlled study of MQF-OK therapy with FT and with UFT on various advanced gastrointestinal cancers. Hirosaki Cooperative Study Group of Cancer Chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Clinical Trials as Top | 1988 |
28 other studies available for tegafur and Cancer of Gastrointestinal Tract
| Article | Year |
|---|---|
Impact of capecitabine and S-1 on anticoagulant activity of warfarin in patients with gastrointestinal cancer.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Capecitabine; Drug Combinations; Drug Interactions; | 2016 |
Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclophosphamide | 2012 |
Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 2003 |
Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1.
Topics: Aged; Antimetabolites, Antineoplastic; Dacryocystorhinostomy; Drug Combinations; Female; Gastrointes | 2005 |
[Clinical trial on the effect of tegafur (SF-SP)].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Capsules; Carcinoma, Intraductal, Noninfiltrating | 1984 |
[Evaluation of tegafur encapsulated with slow-releasing granules (SF-SP) for patients with cancer of the digestive organs].
Topics: Administration, Oral; Adult; Aged; Capsules; Colonic Neoplasms; Delayed-Action Preparations; Drug Ev | 1984 |
Improved liquid chromatographic assay for serum fluorouracil concentrations in the presence of ftorafur.
Topics: Chromatography, Liquid; Drug Stability; Drug Storage; Fluorouracil; Gastrointestinal Neoplasms; Huma | 1981 |
High-dose therapy with ftorafur in gastrointestinal cancer.
Topics: Animals; Carcinoma, Ehrlich Tumor; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplas | 1981 |
[A clinical investigation of the combination therapy of 1-(2-tetrahydrofuryl)-5-fluorouracil (FH) fine granules and 5-FU dry syrup].
Topics: Adult; Aged; Blood Platelets; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neop | 1982 |
[Pharmacodynamic study on the effectiveness of UFT against cancer of gastro-intestinal (GI) tract].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Fluorouracil; Gast | 1993 |
A case of dermatomyositis triggered by tegafur.
Topics: Antimetabolites, Antineoplastic; Dermatomyositis; Fatal Outcome; Female; Follow-Up Studies; Gastroin | 1997 |
Induction of apoptosis in human tumour xenografts after oral administration of uracil and tegafur to nude mice bearing tumours.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Division; Colonic Neoplasms; Ga | 1998 |
[Gamma-hydroxybutyric acid, a metabolite of UFT, shows anti-angiogenic activities and antitumor effect].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Drug Combinations; Endothelial Growth Facto | 2002 |
Recent development of anti-cancer drugs for treatment of GI malignancies in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothe | 2002 |
[Characteristic pharmacodynamic in 1-(2-tetrahydrofuryl)-5-fluorouracil metabolism and its clinical efficacy in patients with primary hepatoma (author's transl)].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Li | 1978 |
[Ftorafur concentration in the blood and urine of oncological patients].
Topics: Biopharmaceutics; Biotransformation; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Flu | 1977 |
[Clinical studies on FT-207 enteric-coated granule--clinico-pharmacological evaluation and clinical experience (author's transl)].
Topics: Adult; Aged; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle | 1979 |
Chemotherapy of gastrointestinal cancer.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Fluorouracil; Gastrointestinal Neoplasms; Humans; Ne | 1979 |
[Prophylactic effect of allopurinol mouthwash against stomatitis induced by the chemotherapy (PMUE regimen) for gastrointestinal malignancies].
Topics: Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Gastroint | 1991 |
[Combination chemotherapy of UFT with adriamycin (ADM) and cisplatin (CDDP) for advanced gastrointestinal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Col | 1990 |
Tegafur chemotherapy for the treatment of gut and liver cancer.
Topics: Adult; Aged; Female; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Lymphatic Metastasis; Male | 1986 |
[Concentration of 5-FU and tegafur in the ascites fluid in patients with peritonitis carcinomatosa after UFT oral administration].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Fluorouracil; G | 1987 |
[Report on nationwide pooled data and cohort investigation in UFT phase II study].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Sche | 1987 |
[Intraperitoneal (Ip) administration of cisplatin in combination with systemic chemotherapy in patients with malignant ascites of gastrointestinal cancer: clinical evaluation and pharmacokinetics].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Cisplatin; D | 1988 |
[Evaluation of a combination of UFT, MMC, and OK-432 for advanced gastro-intestinal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Gastrointestinal Neop | 1987 |
Sensitivity test for 5-fluorouracil and its analogues, 1-(2-tetrahydrofuryl)-5-fluorouracil, uracil/1-(2-tetrahydrofuryl)-5-fluorouracil (4:1) and 1-hexylcarbamoyl-5-fluorouracil, using the subrenal capsule assay.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance; Fluorouracil; Gastrointest | 1988 |
Phase I and pharmacologic study of oral ftorafur and X ray therapy in advanced gastrointestinal cancer.
Topics: Administration, Oral; Adult; Aged; Combined Modality Therapy; Drug Evaluation; Female; Fluorouracil; | 1985 |
Relevance of the pharmacology of oral tegafur to its use as a 5-FU pro-drug.
Topics: Administration, Oral; Fluorouracil; Gastrointestinal Neoplasms; Humans; Injections, Intravenous; Kin | 1985 |